Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. · 2020

Read Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. by Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7025157.txt.

Introduction

Arbyn and co-authors estimate the worldwide burden of cervical cancer in The Lancet Global Health. Persistent human papillomavirus infection is the main cause of this cancer, and vaccines plus virus testing now make prevention realistic. The World Health Organization aims to eliminate cervical cancer as a public health problem during the 21st century. A firm baseline is needed to judge that push.

The team drew estimates for 185 countries from the Global Cancer Observatory 2018 database and the WHO mortality database. They calculated new cases and deaths for 2018, with rates adjusted for age and grouped by region and by development level. Burden varied sharply across the world, falling hardest on lower-resource countries. The figures give the elimination campaign its starting line.

Catalog record

CREATORArbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7025157

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis By Marc Arbyn, Elisabete Weiderpass, Laia Bruni, Silvia de Sanjosé, Mona Saraiya, Jacques Ferlay, Freddie Bray Published in: The Lancet. Global Health DOI: 10.1016/S2214-109X(19)30482-6 ABSTRACT Summary Background The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative. Methods For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis. Findings Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed. Interpretation Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening—including self-sampling—has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem. Funding Belgian Foundation Against Cancer, DG Research and Innovation of the European Commission, and The Bill & Melinda Gates Foundation. INTRODUCTION 10 years ago, cervical cancer ranked as the third most common cancer among women worldwide. However, in 42 low-resource countries, it was the most common cancer in women.1 The knowledge that persistent infection with carcinogenic human papillomavirus (HPV) types is the main cause in triggering the development of cervical cancer has opened new pathways for primary and secondary prevention.2 The implementation of both methods of prevention can make cervical cancer occurrence and death largely avoidable. Consistent evidence indicates that the licensed bivalent and quadrivalent HPV vaccines containing HPV16 and HPV18 antigens protect with high efficacy against infection and precancerous cervical lesions associated with these types when individuals are not yet exposed.3 Both types jointly cause 70–75% of all cervical cancers and 40–60% of its precursors.4, 5 In the past few years, a nonavalent vaccine has also been licenced, which protects against seven carcinogenic HPV types that, together, cause approximately 90% of cervical cancers.6 Research in contextEvidence before this studyThe Global Cancer Observatory (GLOBOCAN) is a regularly-updated database, compiled by the International Agency for Research on Cancer, of global estimates of incidence and mortality rate for 36 cancers and for all cancers combined. For compiling the estimates, recorded data of high quality from national or subnational cancer registry sources are used where possible, otherwise the best available local sources are used in their absence. Previous GLOBOCAN estimates for 2008 indicated that approximately 530 000 cervical cancer cases and 275 000 deaths had occurred worldwide, with 85% of cases occurring in less developed countries. The estimated annual age-standardised incidence rate (ASIR) was 15 per 100 000 women globally and ranged from less than 1 to 56 per 100 000. Cervical cancer was the leading cause of cancer-related death among women in sub-Saharan Africa, central America, south-central Asia, and Melanesia.Added value of this studyOur study provides updated estimates of the cervical cancer burden 10 years after the 2008 GLOBOCAN publication. In 2018, cervical cancer remained a major public health problem, ranking as the fourth most common cause of cancer incidence and mortality in women worldwide. Cervical cancer was the main cause of cancer-related deaths in women in eastern, middle, southern, and western Africa. We observed a significant positive correlation between national ASIRs and corresponding estimates of human papillomavirus (HPV) prevalence. The 2018 estimates presented here provide a baseline to measure the future achievements regarding the ambitious rollout of the WHO Global Initiative to eliminate cervical cancer as a public health problem in every country of the world.Implications of all the available evidenceToday, new tools of primary prevention (prophylactic HPV vaccination) and secondary prevention (screening with validated HPV assays and treatment of cervical precancerous lesions) have been shown to be effective. The ambition of WHO is to reduce the ASIR of cervical cancer to less than 4 per 100 000 women worldwide by vaccinating 90% of all girls by age 15 years, screening 70% of women twice in the age range of 35–45 years, and treating at least 90% of all precancerous lesions detected during screening. Modellers have estimated that this goal might be reached within a few decades in high-resource countries, but might take until the end of the 21st century for the goal to be reached in the lowest-resource countries. Nevertheless, the return of investment will be highest in low-resource countries; for example, using the cumulative incidence estimates from GLOBOCAN and assuming 70% HPV vaccination effectiveness, we can calculate that only 20 girls would need to be vaccinated in eSwatini (the country with the highest estimated incidence) to avoid one case of cervical cancer, whereas the equivalent number needed would be 238 girls in the USA. Ensuring the availability of recorded data of good quality from population-based cancer registries will be essential for monitoring local progress towards the cervical cancer elimination goal. The treatment of precancerous lesions detected by microscopic inspection of cells scraped from the cervix has been the paradigm of secondary prevention of cervical cancer

Read the complete text